Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Home Depot enters its November earnings window with the options market making its most bullish statement in months, even as the stock sits 11% below where it traded 30 days ago.
The clearest shift this week is in options positioning, and it cuts against the cautious tone of recent weeks. The put/call ratio has dropped to 0.70, nearly two standard deviations below its 20-day average of 0.78. That is the most call-skewed reading in at least a month, close to the 52-week low of 0.66. A week ago, the previous note described how the bullish options posture had faded; it has now reasserted itself. Buyers are reaching for calls on a stock that has fallen hard, which reads as either tactical bottom-fishing or genuine conviction that the selloff has gone too far.
Short interest, by contrast, has stabilised rather than retreated. SI edged up roughly 2% on the week to 1.10% of the free float, extending the rebuilding trend flagged in the September 30 note. The month-on-month move is now 7%, a meaningful accumulation from what was already a low base. Borrow costs eased to 0.31%, down 5% on the week, and availability remains essentially unlimited: the shares available to lend dwarf the current short position by orders of magnitude. There is no mechanical pressure on short holders, no squeeze dynamic, and no sign that the borrow market is tightening to constrain further positioning. The short build looks measured, not aggressive.
The Street remains broadly constructive but has been trimming its ambitions. Most recent analyst activity clusters around August earnings, where the dominant move was cuts to price targets alongside maintained Buy ratings: UBS came down from $430 to $420, Bernstein more recently lowered to $344 while keeping a Market Perform. The mean target sits near $377, implying roughly 31% upside from the current $286.69. That gap is wide enough to be meaningful, but it reflects a stock that has derated sharply. The PE has compressed about 2.3 points over the past 30 days to 18.2x, and price-to-book has fallen by a similar margin to 13.6x. Bulls point to structural tailwinds: aging housing stock, chronic undersupply, and strengthening Pro demand supported by the SRS and GMS acquisitions. Bears counter that transaction counts remain negative, big-ticket project sales are still soft, and that tariff cost pressures and integration drag from lower-margin wholesale assets may keep margins under pressure even if comps recover. The dividend factor score ranks in the 98th percentile, a reminder that income buyers are not going anywhere.
Retail attention, as measured by Wikipedia page views and ORTEX stock page traffic, has drifted below its own recent baseline, with a z-score of roughly negative 1.6 against the trailing 90 days. That is consistent with a stock that has been quietly falling rather than attracting crisis-level attention or speculative interest.
Insider activity over the past 90 days has been net negative at around $3.3 million in open-market sales, though the recent transactions are mostly tax-withholding filings (transaction code F) rather than discretionary sales. The one notable open-market sale was General Counsel Teresa Wynn Roseborough selling approximately $807,000 worth of stock at $328.77 in late August. There have been no open-market purchases in the window. BlackRock added nearly 2.9 million shares in its most recent reported period, and Charles Schwab Investment Management added 3.2 million, both signals of passive-flow strength rather than active conviction.
The next print is due November 17. With the PCR at a near-year low, short interest quietly building, and the stock down 11% in a month while the mean analyst target implies more than 30% upside, the tension heading into that date is whether the call buyers are early or simply wrong about the pace of any housing-market recovery.
See the live data behind this article on ORTEX.
Open HD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
